SEC
SlamSEC
Search
Browse
Earnings
BioNexus Gene Lab Corp
Nasdaq:
BGLC
Services-Medical Laboratories
·
KUALA LUMPUR, N8
Overview
All Filings
Sum Fin
Credit
Insiders
Governance
Overview
All Filings
Sum Fin
Credit
Insiders
Governance
Summary Financials
BioNexus Gene Lab Corp — SlamSEC
Revenue
$9.8M
-10.6% YoY
FY 2024
Adj. EBITDA
-$2.6M
-26.1% margin
FY 2024
Net Income
-$2.6M
-26.9% margin
FY 2024
EPS (Diluted)
-$0.17
FY 2024
Stock Price
$2.29
-8.4%
2026-03-10
52W Range
$1.92 – $15.60
P/E Ratio
-13.8x
Market Cap
$4.1M
Cash
$859,076
FY 2021
Total Debt
—
Net Cash
$859,076
FY 2024
Enterprise Value
$3.3M
Debt / EBITDA
0.3x
FY 2024
EV / EBITDA
-1.3x
Employees
—